JO3177B1 - تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول - Google Patents

تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول

Info

Publication number
JO3177B1
JO3177B1 JOP/2012/0074A JOP20120074A JO3177B1 JO 3177 B1 JO3177 B1 JO 3177B1 JO P20120074 A JOP20120074 A JO P20120074A JO 3177 B1 JO3177 B1 JO 3177B1
Authority
JO
Jordan
Prior art keywords
octylphenyl
diol
propane
formulations
ethyl
Prior art date
Application number
JOP/2012/0074A
Other languages
English (en)
Inventor
Rane Supriya
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45953284&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3177(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3177B1 publication Critical patent/JO3177B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

تركيبة صيدلية صلبة مناسبة للتناول الفموي تشتمل على : (أ‌) معدل مستقبل S1P؛ (ب‌) ماليء، و (ت‌) دكسترين حلقي
JOP/2012/0074A 2011-04-01 2012-03-29 تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول JO3177B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470747P 2011-04-01 2011-04-01
US201161545835P 2011-10-11 2011-10-11

Publications (1)

Publication Number Publication Date
JO3177B1 true JO3177B1 (ar) 2018-03-08

Family

ID=45953284

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0074A JO3177B1 (ar) 2011-04-01 2012-03-29 تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول

Country Status (35)

Country Link
US (5) US9592208B2 (ar)
EP (2) EP3143990B1 (ar)
JP (1) JP6019101B2 (ar)
KR (1) KR102027014B1 (ar)
CN (1) CN103476400B (ar)
AR (1) AR085749A1 (ar)
AU (1) AU2012236357B2 (ar)
BR (1) BR112013024430B1 (ar)
CA (1) CA2831600C (ar)
CL (1) CL2013002810A1 (ar)
CO (1) CO6771459A2 (ar)
CY (2) CY1118423T1 (ar)
DK (2) DK3143990T3 (ar)
EA (2) EA027721B1 (ar)
EC (1) ECSP13012912A (ar)
ES (2) ES2773482T3 (ar)
GT (1) GT201300227A (ar)
HK (1) HK1190309A1 (ar)
HR (2) HRP20170021T1 (ar)
HU (1) HUE031286T2 (ar)
IL (1) IL228250B (ar)
JO (1) JO3177B1 (ar)
LT (2) LT3143990T (ar)
MA (1) MA34981B1 (ar)
MX (1) MX342522B (ar)
MY (2) MY175633A (ar)
PE (2) PE20140162A1 (ar)
PL (2) PL2694037T3 (ar)
PT (2) PT2694037T (ar)
RS (1) RS59917B1 (ar)
SG (1) SG193256A1 (ar)
SI (2) SI3143990T1 (ar)
TW (1) TWI528958B (ar)
WO (1) WO2012135561A1 (ar)
ZA (1) ZA201306636B (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
CN103222966A (zh) * 2013-04-01 2013-07-31 北京万全德众医药生物技术有限公司 一种含有盐酸芬戈莫德的固体药物组合物及其制备方法
WO2015015254A1 (en) 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
CZ285953B6 (cs) 1995-12-28 1999-12-15 Yoshitomi Pharmaceutical Industries, Ltd. Vnější přípravek pro topické podání
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
EP2030614A1 (en) 1997-02-27 2009-03-04 Novartis AG Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin
KR100551931B1 (ko) 1997-04-04 2006-02-16 미츠비시 웰파마 가부시키가이샤 2-아미노프로판-1,3-디올 화합물, 이것의 의약으로서의 용도 및 합성 중간체
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
DE122011100047I1 (de) * 2003-04-08 2011-12-15 Mitsubishi Tanabe Pharma Corp Feste pharmazeutische darreichungsformen mit einemS1P rezeptoragonisten und einem zuckeralkohol.
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
MX2007006706A (es) 2004-12-06 2007-10-18 Univ Virginia Analogos de esfingosina 1-fosfato amida de arilo.
GB0502358D0 (en) * 2005-02-04 2005-03-16 Novartis Ag Organic compounds
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP3103448B1 (en) 2006-09-26 2019-07-03 Novartis Ag Pharmaceutical compositions comprising an s1p modulator
EP2120575A4 (en) 2006-12-21 2011-04-27 Abbott Lab AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS
RU2010118457A (ru) 2007-10-12 2011-11-20 Новартис АГ (CH) Композиции, содержащие модуляторы рецептора сфингозин-1-фосфата (sip)
EP2358660A2 (en) 2008-11-11 2011-08-24 Novartis AG Salts of fingolimod
AR074826A1 (es) 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p

Also Published As

Publication number Publication date
JP2014509652A (ja) 2014-04-21
MY175633A (en) 2020-07-02
SG193256A1 (en) 2013-10-30
US20190247335A1 (en) 2019-08-15
EA201391442A1 (ru) 2014-04-30
AU2012236357B2 (en) 2016-03-10
CL2013002810A1 (es) 2014-02-14
PL3143990T3 (pl) 2020-05-18
TWI528958B (zh) 2016-04-11
PL2694037T3 (pl) 2017-05-31
AU2012236357A1 (en) 2013-10-10
HRP20170021T1 (hr) 2017-03-10
MA34981B1 (fr) 2014-03-01
MX2013011415A (es) 2013-12-09
CN103476400A (zh) 2013-12-25
PT2694037T (pt) 2017-01-17
HRP20200249T1 (hr) 2020-05-15
PE20170913A1 (es) 2017-07-12
US20170135967A1 (en) 2017-05-18
EP2694037B1 (en) 2016-10-12
BR112013024430B1 (pt) 2022-02-08
EA027721B1 (ru) 2017-08-31
CO6771459A2 (es) 2013-10-15
JP6019101B2 (ja) 2016-11-02
US20200276137A1 (en) 2020-09-03
ZA201306636B (en) 2014-05-28
CA2831600C (en) 2020-04-21
RS59917B1 (sr) 2020-03-31
LT3143990T (lt) 2020-02-25
EA201790436A2 (ru) 2017-10-31
MX342522B (es) 2016-10-03
ES2610966T3 (es) 2017-05-04
CN103476400B (zh) 2016-11-09
IL228250B (en) 2020-09-30
SI2694037T1 (sl) 2017-01-31
DK3143990T3 (da) 2020-03-02
EP3143990B1 (en) 2019-11-27
PE20140162A1 (es) 2014-02-12
KR20140014194A (ko) 2014-02-05
US9592208B2 (en) 2017-03-14
NZ615023A (en) 2016-07-29
WO2012135561A1 (en) 2012-10-04
HUE031286T2 (hu) 2017-06-28
HK1190309A1 (zh) 2014-07-04
KR102027014B1 (ko) 2019-09-30
CY1118423T1 (el) 2017-06-28
ECSP13012912A (es) 2013-11-29
TW201244711A (en) 2012-11-16
US20180193291A1 (en) 2018-07-12
EP2694037A1 (en) 2014-02-12
AR085749A1 (es) 2013-10-23
EA035686B1 (ru) 2020-07-27
DK2694037T3 (en) 2017-01-16
ES2773482T3 (es) 2020-07-13
SI3143990T1 (sl) 2020-03-31
EA201790436A3 (ru) 2018-03-30
US20140371323A1 (en) 2014-12-18
CA2831600A1 (en) 2012-10-04
MY163746A (en) 2017-10-31
BR112013024430A2 (pt) 2016-12-20
CY1122868T1 (el) 2021-05-05
LT2694037T (lt) 2017-01-10
PT3143990T (pt) 2020-03-04
EP3143990A1 (en) 2017-03-22
GT201300227A (es) 2015-05-05

Similar Documents

Publication Publication Date Title
JO3177B1 (ar) تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
CY1123434T1 (el) Λυοφιλοποiημενα νανοεναιωρηματα φαρμακων
PH12017501495A1 (en) Dosage regimen of an s1p receptor modulator
IL228709A0 (en) Dosage unit form for oral administration
MX2012013021A (es) Formulaciones resistentes a alcohol.
MX2013013204A (es) Sistema de suministro de farmaco.
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
TN2013000396A1 (en) Formulations comprising 2 -amino- 2- [2- (4 - octylphenyl) ethyl] propane -1, 3 - diol
HUE040419T2 (hu) Analgetikus gyógyászati kompozíció orális beadásra
AR124661A2 (es) Formulaciones
EA201992463A1 (ru) Система доставки лекарственного средства